[go: up one dir, main page]

MA69177A1 - Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques - Google Patents

Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques

Info

Publication number
MA69177A1
MA69177A1 MA69177A MA69177A MA69177A1 MA 69177 A1 MA69177 A1 MA 69177A1 MA 69177 A MA69177 A MA 69177A MA 69177 A MA69177 A MA 69177A MA 69177 A1 MA69177 A1 MA 69177A1
Authority
MA
Morocco
Prior art keywords
formula
bcl6
quinolone
tricyclic
bifunctional
Prior art date
Application number
MA69177A
Other languages
English (en)
Inventor
Matthew H. Mcneill
James Paul LAJINESS
Kevin M. Oberg
Joshua D. Hansen
Matthew D. Correa
Jeffrey A. ENGELMAN
Joel D. LEVERSON
Tami J. MARRONE
Mark A. Nagy
Kristin D. SCHLEICHER
Andrew VALIERE
Ming Yan
Original Assignee
Treeline Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeline Biosciences, Inc. filed Critical Treeline Biosciences, Inc.
Publication of MA69177A1 publication Critical patent/MA69177A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne des composés de formule (I) (par exemple, formule (I-aa) (par exemple, formule (I-aa-1), (I-aa-2), (I-aa-3), (I-aa-4), (I-aa-5) ou (I-aa-6)), formule (I-a) (par exemple, formule (I-a-1), (I-a-2), (I-a-3), (I-a-4), (I-a-5) ou (I-a-6)), formule (I-bb) (par exemple, formule (I-bb-1) ou (I-bb-2)) ou formule (I-b) (par exemple, formule (I-b-1) ou (I-b-2))) ou formule (II), ou un sel pharmaceutiquement acceptable de celui-ci, qui induisent la dégradation d'une protéine BCL6. Ces composés sont utiles, par exemple, pour traiter un cancer chez un sujet (par exemple, un être humain). La présente divulgation concerne également des compositions contenant les composés selon la divulgation ainsi que leurs procédés d'utilisation et de fabrication.
MA69177A 2022-06-06 2023-06-05 Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques MA69177A1 (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202263349415P 2022-06-06 2022-06-06
US202263349420P 2022-06-06 2022-06-06
US202263356390P 2022-06-28 2022-06-28
US202263356388P 2022-06-28 2022-06-28
US202263414349P 2022-10-07 2022-10-07
US202263414409P 2022-10-07 2022-10-07
US202263414362P 2022-10-07 2022-10-07
US202263414418P 2022-10-07 2022-10-07
US202263420385P 2022-10-28 2022-10-28
US202263420398P 2022-10-28 2022-10-28
US202363444792P 2023-02-10 2023-02-10
US202363444769P 2023-02-10 2023-02-10
US202363497061P 2023-04-19 2023-04-19
US202363501080P 2023-05-09 2023-05-09
PCT/US2023/067927 WO2023240038A1 (fr) 2022-06-06 2023-06-05 Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques

Publications (1)

Publication Number Publication Date
MA69177A1 true MA69177A1 (fr) 2025-05-30

Family

ID=87136318

Family Applications (1)

Application Number Title Priority Date Filing Date
MA69177A MA69177A1 (fr) 2022-06-06 2023-06-05 Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques

Country Status (15)

Country Link
US (2) US20250276981A1 (fr)
EP (1) EP4536650A1 (fr)
JP (1) JP2025523390A (fr)
KR (1) KR20250021371A (fr)
CN (1) CN119317623A (fr)
AU (1) AU2023284418A1 (fr)
CL (1) CL2024003752A1 (fr)
CO (1) CO2024017749A2 (fr)
CR (1) CR20250001A (fr)
IL (1) IL317218A (fr)
MA (1) MA69177A1 (fr)
MX (1) MX2024015036A (fr)
PE (1) PE20250756A1 (fr)
TW (1) TW202415665A (fr)
WO (1) WO2023240038A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025195363A1 (fr) * 2024-03-18 2025-09-25 正大天晴药业集团股份有限公司 Composé contenant une structure lactame

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021074620A1 (fr) * 2019-10-14 2021-04-22 Cancer Research Technology Limited Dérivés de [1,4]oxazépino[2,3-c]quinolinone utilisés en tant qu'inhibiteurs de blc6
WO2021077010A1 (fr) * 2019-10-17 2021-04-22 Arvinas Operations, Inc. Molécules bifonctionnelles contenant une fraction de liaison à l'ubiquitine ligase e3 liée à une fraction ciblant bcl6
WO2021127586A1 (fr) * 2019-12-20 2021-06-24 Calico Life Sciences Llc Agents de dégradation de protéine tyrosine phosphatase et leurs méthodes d'utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
WO2010008436A1 (fr) 2008-06-24 2010-01-21 Albert Einstein College Of Medicine Of Yeshiva University Procédés et compositions pour l’inhibition de la répression de bcl6
WO2014204859A2 (fr) 2013-06-17 2014-12-24 Melnick Ari Inhibiteurs de bcl6 utilisables en tant qu'agents anticancéreux
JP6999688B2 (ja) 2016-12-13 2022-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｌ６阻害剤としての新規の６－アミノキノリノン化合物および誘導体
KR102828518B1 (ko) 2017-05-26 2025-07-04 캔써 리서치 테크놀로지 리미티드 벤즈이미다졸론 유래된 bcl6의 저해제
EP3630749B9 (fr) 2017-05-26 2024-05-29 Cancer Research Technology Limited Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6
CN108976172B (zh) 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
WO2019119145A1 (fr) 2017-12-21 2019-06-27 Ontario Institute For Cancer Research (Oicr) Inhibiteurs tricycliques de l'interaction protéine-protéine du domaine btb de bcl6 et utilisations associées
EP3728232B1 (fr) 2017-12-22 2023-08-30 Ontario Institute for Cancer Research (OICR) Nouveaux composés de quinolone utilisés en tant qu'inhibiteurs de l'interaction protéine-protéine du domaine bcl6 btb et/ou en tant qu'agents de dégradation de bcl6
WO2019119144A1 (fr) 2017-12-22 2019-06-27 Ontario Institute For Cancer Research (Oicr) Nouveaux composés deutériés comme inhibiteurs de l'interaction protéine-protéine à domaine bcl6 btb et/ou comme agents de dégradation bcl6
CA3088025A1 (fr) 2018-02-06 2019-08-15 Ontario Institute For Cancer Research (Oicr) Inhibiteurs de l'interaction proteine-proteine du domaine bcl6 btb et leurs utilisations
KR20250105504A (ko) 2018-04-13 2025-07-08 캔써 리서치 테크놀로지 리미티드 Bcl6 저해제
US20210330672A1 (en) 2018-07-13 2021-10-28 Teqla Therapeutics Inc. Use of bcl6 inhibitors for treating autoimmune diseases
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
JP7662625B2 (ja) 2019-10-21 2025-04-15 セルジーン コーポレーション 血液がんの治療方法ならびに２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンに対するコンパニオンバイオマーカーの使用
CR20230516A (es) 2021-04-16 2024-01-23 Arvinas Operations Inc Moduladores de la proteólisis bcl6 y métodos de uso asociados

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021074620A1 (fr) * 2019-10-14 2021-04-22 Cancer Research Technology Limited Dérivés de [1,4]oxazépino[2,3-c]quinolinone utilisés en tant qu'inhibiteurs de blc6
WO2021077010A1 (fr) * 2019-10-17 2021-04-22 Arvinas Operations, Inc. Molécules bifonctionnelles contenant une fraction de liaison à l'ubiquitine ligase e3 liée à une fraction ciblant bcl6
WO2021127586A1 (fr) * 2019-12-20 2021-06-24 Calico Life Sciences Llc Agents de dégradation de protéine tyrosine phosphatase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
IL317218A (en) 2025-01-01
JP2025523390A (ja) 2025-07-23
US20240287091A1 (en) 2024-08-29
CR20250001A (es) 2025-05-14
CL2024003752A1 (es) 2025-03-14
CO2024017749A2 (es) 2025-01-13
WO2023240038A1 (fr) 2023-12-14
PE20250756A1 (es) 2025-03-13
KR20250021371A (ko) 2025-02-12
EP4536650A1 (fr) 2025-04-16
US20250276981A1 (en) 2025-09-04
TW202415665A (zh) 2024-04-16
MX2024015036A (es) 2025-01-09
CN119317623A (zh) 2025-01-14
AU2023284418A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA28747B1 (fr) Dérivés de pyridine
MA26877A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
TNSN97212A1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent.
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
FR2708605A1 (fr) Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
ES8206440A1 (es) Un procedimiento para la preparacion del enantiomero (-) de la n-metil-3-(2metilfenoxi)-3-fenilpropilamina.
ZA976705B (en) Process for the synthesis of protected esters of (S)-3,4-dihydroxybutric acid.
FR2708606A1 (fr) Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
EA200200374A1 (ru) Производные хинолилпропилпиперидина, их получение и содержащие их композиции
FR2708608A1 (fr) Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
MX2024015265A (es) Degradadores heterobifuncionales de bcl6 de 1,8-naftiridin-2-ona
IL129026A0 (en) Sulfonamide interleukin-1beta converting enzyme inhibitors
MA69177A1 (fr) Agents de dégradation bifonctionnels de quinolone-bcl6 tricycliques
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
IL145529A0 (en) Cell adhesion-inhibiting antiflammatory and immune-suppressive compounds
MX2024013537A (es) Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina
MX2024015240A (es) Degradadores bifuncionales de bcl6 de quinolona
FR2450833A1 (fr) Derives de benzazepine
ATE317381T1 (de) Sulfonamid-substituierte asparaginsäuren als inhibitoren von interleukin-1beta-konvertierenden enzymen
FR2434572A1 (fr) Derives d'oximes pour la protection des cultures
CA2326710A1 (fr) Nouveaux derives de dihydrofuro-¬3,4-b|quinolein-1-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent